Adaptive Phage Therapeutics, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Adaptive Phage Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2023).
SEC Form D · Jun 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2023
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Adaptive Phage Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Gregory L. Merril | Executive officer | Jun 2023 |
| Michael L. Orndorff | Executive officer | Jun 2023 |
| Subhendu L. Basu | Executive officer | Jun 2023 |
| Carl R. Merril | Executive officer | May 2021 |
| Carl R. Merril | Director | Jun 2023 |
| Evan L. Loh | Director | Jun 2023 |
| Gregory L. Merril | Director | Jun 2023 |
| Ian L. Hardy | Director | Jun 2023 |
| Jana L. Jensen | Director | Jun 2023 |
| Jesse L. Goodman | Director | Jun 2023 |
| Jonathan L. Leff | Director | Jun 2023 |
| Martin L. Heidecker | Director | Jun 2023 |
| Raymond L. Martz | Director | Jun 2023 |
| Gregory L. Merril | Promoter | Jun 2023 |